Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rasagiline mesylate
Drug ID BADD_D01916
Description Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Indications and Usage For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
Marketing Status Prescription
ATC Code N04BD02
DrugBank ID DB01367
KEGG ID D02562
MeSH ID C031967
PubChem ID 3052775
TTD Drug ID D06OMW
NDC Product Code 68546-229; 66039-878; 55111-900; 0378-1270; 57741-1900; 65015-775; 57741-2000; 43451-004; 68546-142; 23155-747; 0378-1271; 23155-746; 82245-0114; 65035-133
Synonyms rasagiline | N-2-propynyl-1-indanamine | AGN 1135 | AGN-1135 | TVP 1022 | TVP1022 | TVP-1022 | N-propargyl-1-aminoindan mesylate | rasagiline hydrochloride | TVP 101 | TVP-101 | 2,3-dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride | Azilect
Chemical Information
Molecular Formula C13H17NO3S
CAS Registry Number 161735-79-1
SMILES CS(=O)(=O)O.C#CCNC1CCC2=CC=CC=C12
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Somnolence19.02.05.003; 17.02.04.006--
Stomatitis07.05.06.005--
Strabismus17.17.01.009; 06.05.02.004--Not Available
Stupor19.02.05.004; 17.02.04.007--Not Available
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Tenosynovitis15.07.01.004--Not Available
Thrombocytosis01.08.02.001--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tongue disorder07.14.01.002--Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.007--Not Available
Tremor17.01.06.002--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urethral disorder20.07.01.002--Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary retention20.02.02.011--
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vaginal discharge21.08.02.002--
Vaginal haemorrhage21.08.01.001; 24.07.03.005--
Vaginal infection21.14.02.002; 11.01.10.002--
Vaginal inflammation21.14.02.001--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Ventricular extrasystoles02.03.04.007--Not Available
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
Vertigo17.02.12.002; 04.04.01.003--
Vestibular disorder17.02.02.008; 04.04.02.001--
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Vomiting07.01.07.003--
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
The 8th Page    First    Pre   8 9 10    Next   Last    Total 10 Pages